Benitec Biopharma Ltd (BNTC)
NASDAQ:BNTC
Want to see BNTC full AI Analyst Report?
Top Page
Benitec Biopharma
(NASDAQ:BNTC)
Select Model
Select Model
Rating:53Neutral
Price Target:
$14.00
▼(-0.57% Downside)
Action:ReiteratedDate:04/16/26
The score is primarily constrained by weak financial performance (large losses and ongoing cash burn versus a very small revenue base), partially offset by a strong, low-leverage balance sheet. Technically, momentum is positive with the price above major moving averages, but overbought indicators reduce the technical score. Valuation is also pressured because earnings are negative and there is no dividend support.
Positive Factors
Proprietary ddRNAi platform
Benitec’s ddRNAi platform is a durable technological asset that targets long‑lasting gene suppression. As a platform technology it can support multiple programs across liver and neurodegenerative indications, creating a structural R&D pipeline and long‑term partnership/licensing optionality independent of short‑term market moves.
Negative Factors
Minimal revenue base
The company lacks meaningful commercial revenue, leaving it dependent on capital markets, partnerships, or milestone income to fund operations. Without product sales, recurring cash inflows are absent, making the business model highly reliant on successful clinical progress to convert R&D investment into sustainable revenue streams.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ddRNAi platform
Benitec’s ddRNAi platform is a durable technological asset that targets long‑lasting gene suppression. As a platform technology it can support multiple programs across liver and neurodegenerative indications, creating a structural R&D pipeline and long‑term partnership/licensing optionality independent of short‑term market moves.
Read all positive factors
Benitec Biopharma (BNTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$417.41M
Dividend YieldN/A
Average Volume (3M)150.00K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue GrowthN/A
EPS Growth68.74%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding34,354,336
10 Day Avg. Volume116,408
30 Day Avg. Volume150,004
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)0.00
P/FCF Ratio-17.95
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue235.79
Enterprise Value/Gross Profit-1.99K
Enterprise Value/Ebitda-2.55
Forecast
1Y Price Target
$32.00Price Target Upside127.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.13
Revenue Forecast (FY)N/A
Benitec Biopharma Business Overview & Revenue Model
Company Description
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It i...
How the Company Makes Money
Benitec Biopharma’s business model is typical of an early-stage/pre-revenue biotechnology company: it invests primarily in research and development to advance ddRNAi-based drug candidates and seeks to generate future value by progressing these pro...
Benitec Biopharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
74
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 556.00K | 0.00 | 0.00 | 75.00K | 73.00K | 59.00K |
| Gross Profit | -66.00K | -396.00K | -343.00K | -306.00K | 64.00K | -64.00K |
| EBITDA | -51.33M | -41.70M | -21.41M | -19.15M | -17.85M | -13.45M |
| Net Income | -46.30M | -37.92M | -21.75M | -19.56M | -18.21M | -13.88M |
Balance Sheet | ||||||
| Total Assets | 190.68M | 99.59M | 52.21M | 4.46M | 5.97M | 21.38M |
| Cash, Cash Equivalents and Short-Term Investments | 188.79M | 97.74M | 50.87M | 2.48M | 4.06M | 19.77M |
| Total Debt | 987.00K | 849.00K | 284.00K | 559.00K | 811.00K | 213.00K |
| Total Liabilities | 3.32M | 2.30M | 4.96M | 4.26M | 3.09M | 1.37M |
| Stockholders Equity | 187.36M | 97.30M | 47.25M | 202.00K | 2.88M | 20.01M |
Cash Flow | ||||||
| Free Cash Flow | -18.76M | -23.61M | -19.58M | -18.01M | -15.91M | -13.05M |
| Operating Cash Flow | -18.74M | -23.59M | -19.40M | -18.01M | -15.90M | -12.83M |
| Investing Cash Flow | -17.47K | -18.00K | -179.00K | -1.00K | -13.00K | -221.00K |
| Financing Cash Flow | 130.92M | 70.48M | 68.03M | 16.02M | 0.00 | 22.52M |
Benitec Biopharma Technical Analysis
Positive
14.08
Price Trends
11.38
Positive
11.93
Positive
12.70
Positive
Market Momentum
0.55
Negative
74.50
Negative
91.52
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Positive. The current price of 14.08 is above the 20-day moving average (MA) of 11.46, above the 50-day MA of 11.38, and above the 200-day MA of 12.70, indicating a bullish trend. The MACD of 0.55 indicates Negative momentum. The RSI at 74.50 is Negative, neither overbought nor oversold. The STOCH value of 91.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTC.
Benitec Biopharma Risk Analysis
Benitec Biopharma disclosed 68 risk factors in its most recent earnings report. Benitec Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Benitec Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $417.41M | -13.08 | -38.92% | ― | ― | 68.74% | |
52 Neutral | $460.54M | -3.10 | -31.75% | ― | 230194.59% | 20.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $379.75M | -2.29 | -65.76% | ― | ― | 26.48% | |
48 Neutral | $432.06M | -3.10 | -71.25% | ― | ― | -3.52% | |
45 Neutral | $418.45M | -62.28 | -5.63% | ― | 153.52% | 72.62% | |
41 Neutral | $28.71M | -1.38 | -81.31% | ― | -64.00% | 91.26% |
* Healthcare Sector Average
BNTC
Benitec Biopharma
12.05
-2.36
-16.38%
TVRD
Tvardi Therapeutics
3.15
-22.30
-87.62%
ASMB
Assembly Biosciences
26.95
15.51
135.58%
RCKT
Rocket Pharmaceuticals
3.48
-4.38
-55.73%
FDMT
4D Molecular Therapeutics
8.87
5.43
157.85%
AURA
Aura Biosciences Inc
7.05
0.98
16.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.